384 related articles for article (PubMed ID: 21427705)
1. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice.
Trang P; Wiggins JF; Daige CL; Cho C; Omotola M; Brown D; Weidhaas JB; Bader AG; Slack FJ
Mol Ther; 2011 Jun; 19(6):1116-22. PubMed ID: 21427705
[TBL] [Abstract][Full Text] [Related]
2. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Wiggins JF; Ruffino L; Kelnar K; Omotola M; Patrawala L; Brown D; Bader AG
Cancer Res; 2010 Jul; 70(14):5923-30. PubMed ID: 20570894
[TBL] [Abstract][Full Text] [Related]
3. Next-generation poly-L-histidine formulations for miRNA mimic delivery.
Kasina V; Wahane A; Liu CH; Yang L; Nieh MP; Slack FJ; Bahal R
Mol Ther Methods Clin Dev; 2023 Jun; 29():271-283. PubMed ID: 37123088
[TBL] [Abstract][Full Text] [Related]
4. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.
Pramanik D; Campbell NR; Karikari C; Chivukula R; Kent OA; Mendell JT; Maitra A
Mol Cancer Ther; 2011 Aug; 10(8):1470-80. PubMed ID: 21622730
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Rupaimoole R; Slack FJ
Nat Rev Drug Discov; 2017 Mar; 16(3):203-222. PubMed ID: 28209991
[TBL] [Abstract][Full Text] [Related]
6. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.
Kasinski AL; Kelnar K; Stahlhut C; Orellana E; Zhao J; Shimer E; Dysart S; Chen X; Bader AG; Slack FJ
Oncogene; 2015 Jul; 34(27):3547-55. PubMed ID: 25174400
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
[TBL] [Abstract][Full Text] [Related]
8. miR-34 - a microRNA replacement therapy is headed to the clinic.
Bader AG
Front Genet; 2012; 3():120. PubMed ID: 22783274
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.
Cheng CJ; Bahal R; Babar IA; Pincus Z; Barrera F; Liu C; Svoronos A; Braddock DT; Glazer PM; Engelman DM; Saltzman WM; Slack FJ
Nature; 2015 Feb; 518(7537):107-10. PubMed ID: 25409146
[TBL] [Abstract][Full Text] [Related]
10. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
11. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
12. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo.
Craig VJ; Tzankov A; Flori M; Schmid CA; Bader AG; Müller A
Leukemia; 2012 Nov; 26(11):2421-4. PubMed ID: 22522790
[No Abstract] [Full Text] [Related]
13. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma.
Babar IA; Cheng CJ; Booth CJ; Liang X; Weidhaas JB; Saltzman WM; Slack FJ
Proc Natl Acad Sci U S A; 2012 Jun; 109(26):E1695-704. PubMed ID: 22685206
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.
Stahlhut C; Slack FJ
Cell Cycle; 2015; 14(13):2171-80. PubMed ID: 25714397
[TBL] [Abstract][Full Text] [Related]
16. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis.
Rokavec M; Öner MG; Li H; Jackstadt R; Jiang L; Lodygin D; Kaller M; Horst D; Ziegler PK; Schwitalla S; Slotta-Huspenina J; Bader FG; Greten FR; Hermeking H
J Clin Invest; 2014 Apr; 124(4):1853-67. PubMed ID: 24642471
[TBL] [Abstract][Full Text] [Related]
17. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells.
Mittelbrunn M; Gutiérrez-Vázquez C; Villarroya-Beltri C; González S; Sánchez-Cabo F; González MÁ; Bernad A; Sánchez-Madrid F
Nat Commun; 2011; 2():282. PubMed ID: 21505438
[TBL] [Abstract][Full Text] [Related]
18. Canonical and non-canonical barriers facing antimiR cancer therapeutics.
Cheng CJ; Saltzman WM; Slack FJ
Curr Med Chem; 2013; 20(29):3582-93. PubMed ID: 23745563
[TBL] [Abstract][Full Text] [Related]
19. MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes.
Porrello ER; Johnson BA; Aurora AB; Simpson E; Nam YJ; Matkovich SJ; Dorn GW; van Rooij E; Olson EN
Circ Res; 2011 Sep; 109(6):670-9. PubMed ID: 21778430
[TBL] [Abstract][Full Text] [Related]
20. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
